NCT05114746 2026-03-16
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04720157 2026-03-11
PSMAddition
Novartis
Phase 3 Active not recruiting
NCT06216249 2026-03-10
Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT04689828 2026-02-20
PSMAfore
Novartis
Phase 3 Active not recruiting
NCT05160597 2026-02-12
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06145633 2026-01-28
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04777071 2026-01-09
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
Phase 2 Active not recruiting
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn
NCT04176497 2025-12-11
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT07209878 2025-10-07
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
Phase 2/3 Recruiting
NCT05324332 2025-09-22
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Peking Union Medical College Hospital
Phase NA Recruiting
NCT03042468 2025-09-17
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT06200103 2025-09-11
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 2 Recruiting
NCT07052214 2025-09-10
BiPASS
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT04951817 2025-08-29
68Ga-PSMA PET/CT for Ra223 Assessment
Chang Gung Memorial Hospital
Phase NA Recruiting
NCT04576871 2025-08-28
Re-treatment 225Ac-J591 for mCRPC
Weill Medical College of Cornell University
Phase EARLY_PHASE1 Completed
NCT07117760 2025-08-12
Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Recruiting
NCT05547386 2025-07-18
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic
Phase 3 Completed
NCT06067269 2025-07-15
HEATWAVE
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT04886986 2025-06-27
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT03582774 2025-05-13
PSMA SRT
Jonsson Comprehensive Cancer Center
Phase 3 Active not recruiting
NCT04597411 2025-03-21
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Recruiting